Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) Patents (Class 424/133.1)
-
Patent number: 11345730Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.Type: GrantFiled: May 11, 2018Date of Patent: May 31, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ DE LIMOGESInventors: Christophe de Romeuf, Christophe Sirac, Jean-Claude Brouet
-
Patent number: 11337965Abstract: The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases.Type: GrantFiled: August 24, 2018Date of Patent: May 24, 2022Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Frederic Geissmann, Elvira Mass, Rocio Vicario
-
Patent number: 11339205Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.Type: GrantFiled: June 6, 2019Date of Patent: May 24, 2022Assignees: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ, ONCOLÓGICA DE VALL HEBRONInventors: Laura Soucek, Marie-Eve Beaulieu
-
Patent number: 11339221Abstract: The present invention relates to bispecific antibody constructs that specifically bind both integrin alpha-V and integrin ?5 (e.g., ?5?1) and methods of making and using those constructs to treat cancer or other pathological conditions involving these integrins.Type: GrantFiled: October 30, 2018Date of Patent: May 24, 2022Assignee: Tufts Medical Center, Inc.Inventor: Paul Mathew
-
Patent number: 11337975Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.Type: GrantFiled: November 22, 2017Date of Patent: May 24, 2022Assignee: Acetylon Pharmaceuticals, Inc.Inventors: Steven Norman Quayle, Simon Stewart Jones, Teru Hideshima, Kenneth C. Anderson
-
Patent number: 11332542Abstract: Disclosed are antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.Type: GrantFiled: September 3, 2019Date of Patent: May 17, 2022Assignee: SANOFIInventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
-
Patent number: 11332537Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.Type: GrantFiled: August 18, 2021Date of Patent: May 17, 2022Assignee: Celldex Therapeutics, Inc.Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
-
Patent number: 11332544Abstract: Genetically engineered antibodies containing non-native N-glycosylated sites, preparation of the antibodies in yeast and fungi, site-specific conjugation of drugs to these antibodies, and methods of treatment utilizing these antibodies are described herein.Type: GrantFiled: April 21, 2017Date of Patent: May 17, 2022Assignee: Merck Sharp & Dohme Corp.Inventors: Robert Davidson, Bing Gong
-
Patent number: 11331372Abstract: The present invention provides methods for the identification of patients with an inflammatory or autoimmune disease that demonstrate an inadequate response to treatment with a multi-Fc therapeutic, and the determination of an optimal dose of a multi-Fc therapeutic for said patient based on the patient's circulating levels of inactivated C3b (iC3b) and/or additional complement components that may be employed as a surrogate for iC3b based on an analogous response to multi-Fc therapeutics. The present invention further provides for improvements in the use of such multi-Fc therapeutics in the treatment of autoimmune and inflammatory diseases.Type: GrantFiled: December 8, 2017Date of Patent: May 17, 2022Assignee: GLIKNIK INC.Inventors: David S. Block, Henrik Olsen
-
Patent number: 11319378Abstract: Provided are an anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and a method of preparing the same. Specifically, provided are a highly stable anti-PD-1/anti-HER2 heterodimeric bispecific antibody having characteristics of a natural IgG and having no mismatched heavy chain and light chain, and a method of preparing the same. The bispecific antibody may bind to both of two kinds of target molecules, and thus may be more effective in treating complex diseases.Type: GrantFiled: November 16, 2017Date of Patent: May 3, 2022Assignee: BEIJING HANMI PHARMACEUTICAL CO., LTD.Inventors: Jiawang Liu, Nanmeng Song, Yaping Yang, Maengsup Kim
-
Patent number: 11319383Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.Type: GrantFiled: March 14, 2017Date of Patent: May 3, 2022Assignee: Universitetet | OsloInventors: Jan Terje Andersen, Stian Foss, Inger Sandlie
-
Patent number: 11318163Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.Type: GrantFiled: November 4, 2019Date of Patent: May 3, 2022Assignee: ENLIVEX THERAPEUTICS LTDInventors: Shai Novik, Dror Mevorach
-
Patent number: 11318138Abstract: Described herein are methods for treating B cell proliferative disorders, in an individual in need thereof. The methods include administering to an individual in need thereof a Btk inhibitor (e.g., ibrutinib), in combination with a CDK4 inhibitor (e.g., palbociclib).Type: GrantFiled: April 26, 2019Date of Patent: May 3, 2022Assignee: Cornell UniversityInventors: Selina Chen-Kiang, Maurizio Di Liberto
-
Patent number: 11312770Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.Type: GrantFiled: November 8, 2018Date of Patent: April 26, 2022Assignee: Xencor, Inc.Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal, Umesh Muchhal
-
Patent number: 11312763Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.Type: GrantFiled: June 23, 2017Date of Patent: April 26, 2022Assignee: Eli Lilly and CompanyInventors: Ronald Bradley Demattos, Michael Carl Irizarry
-
Patent number: 11311575Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2014Date of Patent: April 26, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 11305012Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.Type: GrantFiled: September 23, 2014Date of Patent: April 19, 2022Assignee: MedImmune, LLCInventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto, Andrew Pierce
-
Patent number: 11305005Abstract: This application relates to the field of prevention of pneumonia by administration of a high-dose influenza vaccine.Type: GrantFiled: June 23, 2016Date of Patent: April 19, 2022Assignee: SANOFI PASTEUR INC.Inventors: Carlos DiazGranados, Andrew Dunning
-
Patent number: 11304976Abstract: Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents.Type: GrantFiled: November 19, 2018Date of Patent: April 19, 2022Assignee: ENLIVEX THERAPEUTICS LTDInventors: Shai Novik, Dror Mevorach
-
Patent number: 11306360Abstract: The present application mainly relates to specific methods for inferring activity of a cellular signaling pathway in tissue and/or cells of a medical subject based at least on expression levels of one or more target gene(s) of the cellular signaling pathway measured in an extracted sample of the tissue and/or cells of the medical subject, an apparatus comprising a digital compressor configured to perform such methods and a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such methods.Type: GrantFiled: December 18, 2013Date of Patent: April 19, 2022Assignee: KONINKLIJKE PHILIPS N.V.Inventors: Hendrik Jan Van Ooijen, Wilhelmus Franciscus Johannes Verhaegh, Paul Arnold Van De Wiel
-
Patent number: 11299552Abstract: The present disclosure generally relates to chimeric antigen receptors, more specifically to chimeric antigen receptor compositions and methods for use of the same. The present disclosure also provides for nucleic acid molecules and expression vectors for making and using the chimeric antigen receptors and for co-receptor signaling using such chimeric antigen receptors. The present disclosure also provides methods of treatment using such compositions. The chimeric antigen receptors of the present disclosure interact with the endogenous T-cell receptor complex enabling physiological control of signaling and T-cell response and can be combined with ligands such as co-stimulatory ligands for further controlling and influencing T-cell activation and response.Type: GrantFiled: November 1, 2018Date of Patent: April 12, 2022Assignee: University of KansasInventors: Thomas Yankee, John Szarejko
-
Patent number: 11299551Abstract: Provided are anti-CD19 and anti-CD38 common light chain bispecific antibodies. The anti-CD19 and anti-CD38 bispecific antibodies described herein are useful in methods for treating a cancer or a tumor.Type: GrantFiled: April 13, 2021Date of Patent: April 12, 2022Assignee: Biograph 55, Inc.Inventors: Leonard Presta, Paul Tumeh, Nils Lonberg, Omar Duramad
-
Patent number: 11298354Abstract: The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.Type: GrantFiled: June 9, 2017Date of Patent: April 12, 2022Assignees: DANA-FARBER CANCER INSTITUTE, INC., ACETYLON PHARMACEUTICALS, INC.Inventors: Kwok-kin Wong, Yan Liu, Dennis O. Adeegbe, Steven Norman Quayle
-
Patent number: 11286312Abstract: The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A-X:Y-B) and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets.Type: GrantFiled: December 1, 2016Date of Patent: March 29, 2022Assignee: UCB BIOPHARMA SRLInventors: Pallavi Bhatta, Laura Starkie, Michael John Wright
-
Patent number: 11286293Abstract: The present invention provides heterodimer pairs that can comprise a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain or fragment thereof. At least one of the heterodimers can comprise one or more amino acid modifications in the CH1 and/or CL domains, one or more amino acid modifications in the VH and/or VL domains, or a combination thereof. The modified amino acid(s) can be part of the interface between the light chain and heavy chain and are typically modified to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer typically preferentially pairs with the second light chain rather than first.Type: GrantFiled: September 5, 2018Date of Patent: March 29, 2022Assignee: ZYMEWORKS, INC.Inventors: Adam Louis Corper, Dunja Urosev, Stacey A. L. Tom-Yew, Dustin Weyland Blue Bleile, Thomas Spreter Von Kreudenstein, Surjit Dixit, Paula Irene Lario, Mario Sanches
-
Patent number: 11273155Abstract: A pharmaceutical composition and a therapeutic method wherein an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, and the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to the antibody via a thioether bond; and a pharmaceutical composition and a therapeutic method for use in treatment of a disease that can be ameliorated through an antitumor immunity-activating effect wherein the antibody-drug conjugate is included.Type: GrantFiled: December 11, 2017Date of Patent: March 15, 2022Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tomomi Iwata, Chiaki Ishii, Teiji Wada, Saori Ishida, Yasuki Kamai
-
Patent number: 11267868Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.Type: GrantFiled: April 2, 2014Date of Patent: March 8, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
-
Patent number: 11268152Abstract: In accordance with the present invention, the single gene SERPINA1 has been identified as a significant predictor of survival in ER+ and ER+/HER2+ breast cancer patients. For example, patients with ER+/FIER2+ breast cancer generally have a worse outcome compared to ER+/FIER2? and ER?/FIER2+ patients. Currently there is no known predictive marker for the treatment C outcome of ER+ and ER+/FIER2+ breast cancers, thus the ability of SERPINA1 to predict the survival of this intrinsic subtype of breast cancer patients is valuable.Type: GrantFiled: January 19, 2016Date of Patent: March 8, 2022Assignee: CITY OF HOPEInventors: Shiuan Chen, Hei Jason Chan
-
Patent number: 11267885Abstract: Disclosed herein are antigen binding units that specifically bind to CD47. Further disclosed herein are polynucleic acids encoding said antigen binding units, vectors comprising said polynucleic acids, and hybridomas and host cells comprising said vectors. Further provided herein are methods for inducing phagocytosis of CD47-expressing cells.Type: GrantFiled: January 26, 2018Date of Patent: March 8, 2022Assignee: ZLIP HOLDING LIMITEDInventors: Yangsheng Qiu, Jing Li, Honghai Gao, Fenglan Wu, Xu Fang, Shou Li, Hongtao Lu, James S. Yan, Lei Shi
-
Patent number: 11266744Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.Type: GrantFiled: November 30, 2018Date of Patent: March 8, 2022Assignee: AMGEN INC.Inventors: Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
-
Patent number: 11262358Abstract: Provided are methods of predicting responsiveness of a subject having an inflammatory bowel disease (IBD) to a tumor necrosis factor (TNF)-alpha inhibitor, by analyzing a frequency of at least one subpopulation of immune cells in a tissue biopsy of the subject. Also provided are methods of selecting a treatment for a subject and kits for determining responsiveness of the subject to treatment with a TNF-alpha inhibitor.Type: GrantFiled: April 6, 2017Date of Patent: March 1, 2022Assignees: Technion Research & Development Foundation Limited, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Shai S. Shen-Orr, Elina Starovetsky, Naama Maimon, Purvesh Khatri, Renaud Gaujoux, Francesco Vallania
-
Patent number: 11261253Abstract: Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.Type: GrantFiled: September 5, 2018Date of Patent: March 1, 2022Assignee: Albert Einstein College of MedicineInventor: Xingxing Zang
-
Patent number: 11260124Abstract: To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.Type: GrantFiled: May 20, 2016Date of Patent: March 1, 2022Assignee: Astellas Pharma Inc.Inventors: Hirotsugu Tanaka, Hirotada Fujita, Toshiaki Aoki
-
Patent number: 11261232Abstract: In some aspects the present invention provides methods for the treatment of B-cell lymphomas. Some such methods involve administration of HVEM ectodomain polypeptides, anti-HVEM antibodies, or anti-BTLA antibodies to subjects in need thereof. Some such methods involve use of CAR T cells, such as CD19-specific CAR T cells. The present invention also provides compositions useful in such methods. These and other embodiments of the present invention and described further herein.Type: GrantFiled: April 4, 2016Date of Patent: March 1, 2022Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Michael Henry Boice, Hans Guido Wendel, Darin Salloum
-
Patent number: 11253588Abstract: An effective combined dose of an anti-CD47 agent and an anti-TNF agent is administered to the subject in a dose and for a period of time effective to stabilize, prevent or reduce atherosclerotic plaque in the individual.Type: GrantFiled: February 25, 2016Date of Patent: February 22, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Nicholas J. Leeper, Irving L. Weissman
-
Patent number: 11254753Abstract: The present invention relates to variant antibodies and methods of generating said antibodies with a reduced level of binding to process impurities. In particular, the invention describes variant IgG4 antibodies which have been modified in the heavy chain constant region at any one or a combination of amino acids in the region between Kabat residues 203 and 256, wherein the variant IgG4 antibody has a reduced level of binding to host cell protein (HCP), compared to an unmodified IgG4 antibody. The invention also relates to compositions comprising said variant IgG4 antibodies.Type: GrantFiled: October 3, 2017Date of Patent: February 22, 2022Inventors: Hella Bosteels, Shugui Chen, Kayeleigh Farrow, Richard Kucia-Tran, William John Kenneth Lewis, Andrew S. Thomson, Mark Uden
-
Patent number: 11253606Abstract: The present invention relates to combination therapy with drugs, such as microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or PI3K inhibitors, with antibodies or immunoconjugates against HLA-DR or Trop-2. Where immunoconjugates are used, they preferably incorporate SN-38 or pro-2PDOX. The immunoconjugate may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8 or 10 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.Type: GrantFiled: March 21, 2019Date of Patent: February 22, 2022Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Thomas M. Cardillo
-
Patent number: 11253609Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: GrantFiled: March 2, 2018Date of Patent: February 22, 2022Assignee: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Patent number: 11248045Abstract: Disclosed are a means to convert compounds having physiological or pharmacological activity and unable to pass through the blood-brain barrier into a form that allows them to pass through the blood-brain barrier, and compounds converted thereby. The means is an anti-human transferrin receptor antibody and the converted compounds are molecular conjugates between physiologically active protein or pharmacologically active low-molecular-weight compounds and an anti-human transferrin receptor antibody.Type: GrantFiled: June 24, 2016Date of Patent: February 15, 2022Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Hiroyuki Sonoda, Kenichi Takahashi
-
Patent number: 11248046Abstract: Antibodies and compositions against Claudin 6 and uses thereof are provided.Type: GrantFiled: February 13, 2020Date of Patent: February 15, 2022Assignee: Integral Molecular, Inc.Inventors: Ross Chambers, Joseph Rucker, Thomas Charpentier, Lewis J. Stafford, Brad Screnci, Trevor Barnes, Benjamin Doranz
-
Patent number: 11246907Abstract: The present invention provides an agent, or composition containing an agent, for use in treating or preventing hypercytokinemia in a subject resulting from cytokine release from non-proliferating immune cells in blood, wherein the agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents.Type: GrantFiled: November 13, 2019Date of Patent: February 15, 2022Assignee: Norwegian University of Science and TechnologyInventor: Marit Otterlei
-
Patent number: 11242380Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.Type: GrantFiled: November 13, 2018Date of Patent: February 8, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
-
Patent number: 11242393Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.Type: GrantFiled: March 22, 2019Date of Patent: February 8, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Michelle Renee Kuhne, Alan J. Korman, Haichun Huang, Yiming Yin, Robert F. Graziano, Natalie A. Bezman, Pavel Strop, Richard Y. Huang, Guodong Chen, Mohan Srinivasan, Peter Sung Keun Lee, Gamze Ozlem Camdere
-
Patent number: 11242370Abstract: The present invention relates to neuregulin (NRG) 4 compounds and methods of treatment with NRG4 compounds.Type: GrantFiled: March 31, 2020Date of Patent: February 8, 2022Assignee: Eli Lilly and CompanyInventors: Jonathan Wesley Day, Josef George Heuer, Avinash Muppidi, Wei Ni, James David Pancook
-
Patent number: 11236161Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.Type: GrantFiled: March 21, 2019Date of Patent: February 1, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: James N. Kochenderfer
-
Patent number: 11236170Abstract: The present invention is directed to heterodimeric anti-PD-1 x anti-CTLA-4. Also provided are nucleic acid compositions that encode the antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.Type: GrantFiled: June 7, 2019Date of Patent: February 1, 2022Assignee: Xencor, Inc.Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
-
Patent number: 11236168Abstract: The present inventors have successfully found a large number of Fc variants with remarkably increased binding activity against and/or binding selectivity for mouse Fc?RII by introducing amino acid alteration(s) to the Fc region.Type: GrantFiled: August 23, 2013Date of Patent: February 1, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Eriko Murata, Futa Mimoto
-
Patent number: 11229652Abstract: The invention provides a novel approach to the treatment of autoimmune diseases, particularly multiple sclerosis, using a molecule capable of acting as substrate for the queuine-insertase enzyme complex.Type: GrantFiled: May 10, 2018Date of Patent: January 25, 2022Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLINInventor: Vincent Kelly
-
Patent number: 11230610Abstract: The invention provides bivalent antibodies including two light and heavy chain pairs. The N-termini of one or both light and heavy chain pairs are linked via linkers comprising a protease cleavage site to coiled-coil forming peptides that associate to form a coiled coil reducing binding affinity of at least one light-heavy chain pair to a target.Type: GrantFiled: December 8, 2017Date of Patent: January 25, 2022Assignee: SEAGEN INC.Inventors: Vivian Trang, Matthew R. Levengood, Peter Senter
-
Patent number: 11230568Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.Type: GrantFiled: June 24, 2019Date of Patent: January 25, 2022Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNTVERSITY OF TEXAS SYSTEMInventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby